Press Release: Icosavax : Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc....
Read full article »
Icosavax is a Washington-based biotechnology company that researches and develops VLP vaccines for the treatment of respiratory diseases.
Read more